方盛制药再次实施特别分红 创新中药“三箭齐发”

Group 1 - The core viewpoint of the article emphasizes Hunan Fangsheng Pharmaceutical Co., Ltd.'s commitment to shareholder interests through consistent cash dividends and the implementation of a special dividend [2] - Since its listing, the company has maintained an active and stable cash dividend policy, with a total of 18 dividends amounting to approximately 755 million yuan (including tax, and including the special dividend for 2025), which exceeds its net financing amount of 370 million yuan [2] - To enhance shareholder satisfaction, the company has optimized its dividend mechanism, introducing a "three dividends" policy in 2024, which includes annual, interim, and special dividends [2] Group 2 - Market participants view the high frequency and substantial amount of dividends as a reflection of the company's improving profitability and sustained cash flow, demonstrating management's commitment to rewarding shareholders and sharing development results [3] - The company is recognized for its strong R&D capabilities, implementing an innovation-driven development strategy with increased investment in R&D, particularly in the field of innovative traditional Chinese medicine [3] - A significant milestone is expected in June 2025, with the core product "Yingxue Qufeng Zhitong Granules" receiving drug registration approval, marking a major breakthrough in the company's innovative drug development [3]